Amedisys Inc (AMED) Shares Sold by First Midwest Bank Trust Division

First Midwest Bank Trust Division lowered its stake in Amedisys Inc (NASDAQ:AMED) by 42.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 19,923 shares of the health services provider’s stock after selling 14,868 shares during the period. First Midwest Bank Trust Division owned approximately 0.06% of Amedisys worth $1,115,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in AMED. Federated Investors Inc. PA increased its stake in shares of Amedisys by 2.3% in the second quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock worth $122,000 after purchasing an additional 44 shares during the period. Riverhead Capital Management LLC grew its stake in shares of Amedisys by 75.5% in the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the health services provider’s stock valued at $121,000 after purchasing an additional 831 shares during the period. CIBC Asset Management Inc bought a new stake in shares of Amedisys in the 2nd quarter valued at approximately $230,000. Quantitative Systematic Strategies LLC bought a new stake in shares of Amedisys in the 3rd quarter valued at approximately $205,000. Finally, SG Americas Securities LLC grew its stake in shares of Amedisys by 48.7% in the 2nd quarter. SG Americas Securities LLC now owns 3,743 shares of the health services provider’s stock valued at $235,000 after purchasing an additional 1,226 shares during the period. 94.62% of the stock is owned by institutional investors.

Amedisys Inc (AMED) traded up $0.05 during trading on Tuesday, hitting $56.30. 259,800 shares of the stock were exchanged, compared to its average volume of 322,063. Amedisys Inc has a one year low of $38.00 and a one year high of $65.91. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.33 and a current ratio of 1.33. The firm has a market cap of $1,910.00, a P/E ratio of 26.91, a price-to-earnings-growth ratio of 1.36 and a beta of 0.68.

Amedisys (NASDAQ:AMED) last issued its earnings results on Tuesday, November 7th. The health services provider reported $0.56 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.54 by $0.02. The business had revenue of $380.20 million during the quarter, compared to the consensus estimate of $384.59 million. Amedisys had a net margin of 2.88% and a return on equity of 14.68%. Amedisys’s revenue was up 5.1% on a year-over-year basis. During the same period last year, the business posted $0.36 EPS. analysts expect that Amedisys Inc will post 2.22 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This article was published by Week Herald and is the property of of Week Herald. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://weekherald.com/2017/11/14/first-midwest-bank-trust-division-decreases-position-in-amedisys-inc-amed.html.

Several research analysts have recently commented on AMED shares. Mizuho reissued a “buy” rating and issued a $65.00 target price (up from $55.00) on shares of Amedisys in a report on Wednesday, November 8th. Benchmark Co. reissued a “hold” rating on shares of Amedisys in a report on Thursday, November 9th. Craig Hallum reissued a “buy” rating and issued a $68.00 target price (up from $55.00) on shares of Amedisys in a report on Thursday, November 9th. Robert W. Baird upped their price objective on Amedisys from $50.00 to $60.00 and gave the stock a “neutral” rating in a report on Friday. Finally, SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $70.00 price objective on shares of Amedisys in a report on Friday. Six equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $61.00.

Amedisys Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply